[
    {
        "other_ids": [],
        "amendment_date": null,
        "keywords": null,
        "dcp_id": null,
        "interventional_model": "Single Group",
        "lead_org": "Repare Therapeutics",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 0,
                    "description": "Male or female and \u226512 years-of-age at the time of informed consent."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 1,
                    "description": "Lansky performance status \u226550% for patients \u226416 years of age, or ECOG score of 0, 1, or 2 for patients >16 years of age."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 2,
                    "description": "Locally advanced or metastatic resistant or refractory solid tumors."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 3,
                    "description": "Patients <18 years of age must weigh at least 40 kg."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 4,
                    "description": "Submission of available tumor tissue at screening or willingness to have a biopsy performed if safe and feasible"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 5,
                    "description": "Next generation sequencing (NGS) report obtained in a CLIA-certified or equivalent laboratory demonstrating eligible tumor biomarker."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 6,
                    "description": "Measurable disease as per RECIST v1.1."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 7,
                    "description": "Ability to swallow and retain oral medications."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 8,
                    "description": "Acceptable hematologic and organ function at screening."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 9,
                    "description": "Negative pregnancy test (serum) for women of childbearing potential (WOCBP) at Screening."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 10,
                    "description": "Resolution of all toxicities of prior therapy or surgical procedures."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 11,
                    "description": "Any prior radiation must have been completed at least 7 days prior to the start of study drugs, and patients must have recovered from any acute adverse effects prior to the start of study treatment."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 12,
                    "description": "Chemotherapy or small molecule antineoplastic agent given within 21 days or <5 half-lives, whichever is shorter, prior to first dose of study drug."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 13,
                    "description": "History or current condition, therapy, or laboratory abnormality that might confound the study results or interfere with the patient's participation for the full duration of the study treatment."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 14,
                    "description": "Patients who are pregnant or breastfeeding."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 15,
                    "description": "Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the participating patient's safety."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 16,
                    "description": "Major surgery within 4 weeks prior to first dose of RP-6306."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 17,
                    "description": "Uncontrolled, symptomatic brain metastases."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 18,
                    "description": "Uncontrolled hypertension."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 19,
                    "description": "Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol."
                }
            ],
            "structured": {
                "max_age": "999 Years",
                "max_age_number": 999.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 999.0,
                "gender": "BOTH",
                "accepts_healthy_volunteers": false,
                "min_age": "12 Years",
                "min_age_number": 12.0,
                "min_age_in_years": 12.0
            }
        },
        "completion_date_type_code": "ANTICIPATED",
        "detail_description": "Phase 1, multi-center, open-label, dose-escalation study to:\r\n\r\n        -  Evaluate the safety profile and MTD of RP-6306 alone and in combination with RP-3500\r\n           when administered orally to establish the recommended Phase 2 dose and schedule\r\n\r\n        -  Characterize the PK and pharmacodynamics of RP-6306 alone and in combination with\r\n           RP-3500\r\n\r\n        -  Assess preliminary anti-tumor activity associated with RP-6306 alone and in combination\r\n           with RP-3500",
        "official_title": "Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 Alone or in Combination With RP-3500 in Patients With Advanced Solid Tumors",
        "_phase_sort_order": 4,
        "collaborators": [],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "Up to 90 days after last administration of study intervention",
                "name": "Safety and Tolerability of RP-6306 in combination with RP-3500 in patients with advanced solid tumors as assessed by NCI CTCAE v5.0",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Up to 90 days after last administration of study intervention",
                "name": "Safety and Tolerability of RP-6306 in patients with advanced solid tumors as assessed by NCI CTCAE v5.0",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "for the first 3 months on treatment",
                "name": "To assess the correlation between RP-6306 and RP-3500 dose (mg) and degree of gamma-H2AX induction by immunohistochemistry.",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "for the first 3 months on treatment",
                "name": "To assess the correlation between RP-6306 dose (mg) and degree of inhibition of phospho-CDK1 signal by immunohistochemistry.",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Through Study Completion, an average of 1 year",
                "name": "To assess the percent of patients with a response to RP-6306 and RP-3500 per RECIST v1.1 criteria.",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Through Study Completion, an average of 1 year",
                "name": "To assess the percent of patients with a response to RP-6306 monotherapy per RECIST v1.1 criteria.",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "through study completion, an average of 1 year",
                "name": "To assess the plasma concentrations of RP-6306 monotherapy in the fasted and fed states.",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 90 days after last administration of study intervention",
                "name": "To define the MTD of RP-6306 in combination with RP-3500, and determine a recommended Phase 2 dose (RP2D) and preferred schedule",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Up to 90 days after last administration of study intervention",
                "name": "To define the MTD of RP-6306 monotherapy, and determine a recommended Phase 2 dose (RP2D) and preferred schedule",
                "description": null,
                "type_code": "PRIMARY"
            }
        ],
        "phase": "I",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 2,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT04855656",
        "biomarkers": [],
        "classification_code": null,
        "current_trial_status_date": "2021-05-12",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Metastatic Solid Neoplasm",
                    "Metastatic Malignant Solid Neoplasm",
                    "Metastatic Solid Tumor"
                ],
                "nci_thesaurus_concept_id": "C127155",
                "name": "Metastatic Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263",
                    "C132146"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "Advanced Solid Tumor",
                    "Advanced Solid Neoplasm",
                    "Advanced Non-Hematologic Malignancy",
                    "Advanced Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C129707",
                "name": "Advanced Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9270",
                    "C127155"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Locally Advanced Solid Tumor",
                    "Locally Advanced Malignant Solid Neoplasm",
                    "Locally Advanced Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C133093",
                "name": "Locally Advanced Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C8524",
                    "C127155"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C133737",
                "name": "Refractory Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C132146",
                    "C120186"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Tumor",
                    "Tumor, secondary",
                    "Neoplasm, secondary"
                ],
                "nci_thesaurus_concept_id": "C36255",
                "name": "Secondary Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Tumor, metastatic",
                    "Metastatic Tumor",
                    "Neoplasm, metastatic",
                    "Metastatic"
                ],
                "nci_thesaurus_concept_id": "C3261",
                "name": "Metastatic Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, malignant",
                    "Cancer",
                    "Tumor, malignant, NOS",
                    "Malignancy",
                    "Unclassified tumor, malignant",
                    "Malignant Neoplastic Disease",
                    "Malignant Growth",
                    "CA",
                    "Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C9305",
                "name": "Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Solid Neoplasm",
                    "Solid Tumour",
                    "Solid tumor, NOS"
                ],
                "nci_thesaurus_concept_id": "C9292",
                "name": "Solid Tumor",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Cancer"
                ],
                "nci_thesaurus_concept_id": "C36263",
                "name": "Metastatic Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4968",
                    "C3261"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C132146",
                "name": "Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9292",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease term",
                    "Diseases",
                    "Disease",
                    "Diseases and Disorders",
                    "disease_term",
                    "Diagnosis",
                    "Disease or Disorder, Non-Neoplastic",
                    "disease type",
                    "Disorders",
                    "Disease or Disorder",
                    "Disorder",
                    "condition",
                    "disease_type"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Advanced Cancer"
                ],
                "nci_thesaurus_concept_id": "C9270",
                "name": "Advanced Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Cancer",
                    "Secondary Malignancy"
                ],
                "nci_thesaurus_concept_id": "C4968",
                "name": "Secondary Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36255",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm",
                    "Neoplasms, NOS",
                    "tumor",
                    "Neoplastic Growth",
                    "Tumor, NOS",
                    "Neoplasia",
                    "Neoplasm, NOS",
                    "Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Tumor"
                ],
                "nci_thesaurus_concept_id": "C7628",
                "name": "Refractory Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Refractory Cancer",
                    "resistant cancer",
                    "clinical resistance"
                ],
                "nci_thesaurus_concept_id": "C120186",
                "name": "Refractory Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305",
                    "C7628"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Locally Advanced Cancer",
                    "regional cancer",
                    "Locally advanced",
                    "Locally Metastatic Malignant Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C8524",
                "name": "Locally Advanced Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "RP-6306-01",
        "active_sites_count": 10,
        "lead_org_cancer_center": null,
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Enzyme Inhibitor Drug",
                            "Enzyme Antagonist",
                            "Enzyme Inhibitor Agent"
                        ],
                        "nci_thesaurus_concept_id": "C471",
                        "name": "Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C179323",
                        "name": "PKMYT1 Inhibitor RP-6306",
                        "description": null,
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C129825"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastics",
                            "Anti-Cancer Agents",
                            "Antineoplastic Drugs",
                            "Antiproliferative Agents",
                            "Tumor-Specific Treatment Agents",
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Anti-Tumor Agents",
                            "Antiproliferative Drugs",
                            "Cancer Drug",
                            "Anti-Tumor Drugs"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-cancer Enzyme Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C129825",
                        "name": "Antineoplastic Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C129824",
                            "C471"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Drug Substance",
                            "Pharmaceutical Agent",
                            "Pharmaceuticals",
                            "Drug",
                            "Pharmacologic Agent",
                            "Pharmacological Substance",
                            "Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Protein Antagonist",
                            "Anti-cancer Protein Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C129824",
                        "name": "Antineoplastic Protein Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2189"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2189",
                        "name": "Signal Transduction Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": []
                    }
                ],
                "name": "Arm not specified",
                "description": null,
                "type": null
            },
            {
                "interventions": [],
                "name": "Phase 1: RP-6306 in combination with RP-3500, Dose Escalation Study",
                "description": "Patients receive RP-6306 with RP-3500 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Phase 1: RP-6306 Single-Agent, Dose Escalation and Food-effect Study",
                "description": "Patients receive RP-6306 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.",
                "type": "EXPERIMENTAL"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2021-04132",
        "why_study_stopped": null,
        "brief_summary": "The primary purpose of this study is to assess the safety and tolerability of RP-6306 alone\r\n      and in combination with RP-3500 in patients with eligible advanced solid tumors, determine\r\n      the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.",
        "brief_title": "Study of RP-6306 Alone or in Combination With RP-3500 in Patients With Advanced Solid Tumors",
        "status_history": [
            {
                "status_date": "2021-05-12T00:00:00.000001",
                "status": "ACTIVE"
            },
            {
                "status_date": "2021-04-26T00:00:00",
                "status": "IN_REVIEW"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 120,
        "prior_therapy": [],
        "_current_trial_status_sort_order": 0,
        "start_date": "2021-04-30",
        "record_verification_date": "2022-03-01",
        "ctep_id": null,
        "current_trial_status": "Active",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": null,
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "Non-Randomized Trial"
        },
        "acronym": "MYTHIC",
        "nci_programs": [],
        "nci_funded": "Indirect",
        "anatomic_sites": [
            "Multiple"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": null,
        "study_source": "Industrial",
        "completion_date": "2024-04-30",
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]